Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
EBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsInterest & Investment IncomeNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Roivant Sciences (ROIV) Other Operating Expenses (2020 - 2025)

Historic Other Operating Expenses for Roivant Sciences (ROIV) over the last 6 years, with Q4 2025 value amounting to $700000.0.

  • Roivant Sciences' Other Operating Expenses rose 17027.03% to $700000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $965000.0, marking a year-over-year increase of 3668.56%. This contributed to the annual value of $911000.0 for FY2025, which is 9675.21% down from last year.
  • According to the latest figures from Q4 2025, Roivant Sciences' Other Operating Expenses is $700000.0, which was up 17027.03% from $111000.0 recorded in Q3 2025.
  • Roivant Sciences' 5-year Other Operating Expenses high stood at $16.7 million for Q2 2023, and its period low was $111000.0 during Q3 2025.
  • Moreover, its 5-year median value for Other Operating Expenses was $259000.0 (2024), whereas its average is $3.2 million.
  • Its Other Operating Expenses has fluctuated over the past 5 years, first soared by 86836.62% in 2023, then tumbled by 9872.56% in 2024.
  • Quarter analysis of 5 years shows Roivant Sciences' Other Operating Expenses stood at $853000.0 in 2021, then surged by 102.34% to $1.7 million in 2022, then plummeted by 88.59% to $197000.0 in 2023, then soared by 31.47% to $259000.0 in 2024, then soared by 170.27% to $700000.0 in 2025.
  • Its Other Operating Expenses stands at $700000.0 for Q4 2025, versus $111000.0 for Q3 2025 and $154000.0 for Q2 2025.